Les essais cliniques en cancérologie pédiatrique

  title={Les essais cliniques en canc{\'e}rologie p{\'e}diatrique},
  author={G. Vassal and D. M{\'e}ry-Mignard and C. Caulin and A. Baruchel and A. Benkritly and A. Benzohra and P. Chastagner and R. Defrance and F. Doz and S. Durrleman and J. Gentet and N. Hoog-Labouret and C. Lassale and A. Mathieu-Bou{\'e} and V. M{\'e}resse and N. Milpied and L. Normand and C. Puozzo and R. Serreau and P. Trunet and P. Vella and C. Vergely},
Resume Les cancers de l’enfant et de l’adolescent sont des maladies rares. Malgre les progres therapeutiques accomplis (plus de deux cas sur trois gueris), le cancer demeure la premiere cause de deces par maladie chez l’enfant de plus de 1 an. L’acces a des nouveaux medicaments plus efficaces et / ou mieux toleres est donc une priorite de Sante Publique. Notre table ronde s’est ainsi fixe comme objectif de faire un etat des lieux et de proposer des recommandations visant a faciliter un acces… Expand
4 Citations

Figures from this paper

Pharmacologie en oncologie pédiatrique: particularités
RésuméLa chimiothérapie tient une place centrale dans le traitement des cancers de l’enfant et contribue à guérir plus de trois enfants sur quatre avec les protocoles actuels. Néanmoins, les 25 % desExpand
Spécificités pharmacologiques en oncologie pédiatrique
The specificities of children as compared to adults in the context of clinical drug development and pharmacology research in paediatric oncology are reviewed in order to improve the knowledge of "old" drugs. Expand
End of life care in adolescents and young adults with cancer: experience of the adolescent unit of the Institut Gustave Roussy.
The terminally ill adolescent displays notable challenges to care providers and requires a holistic approach with the help of a multidisciplinary team. Expand
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring
From infants to adults this new dosing enabled, without TDM and dose adjustment, to successfully target a therapeutic AUC window, and a significant difference in Bu clearance was demonstrated. Expand


Autorisation de mise sur le marché et information pédiatrique pour les médicaments de chimiothérapie des cancers : état des lieux et propositions
Resume Le pediatre est souvent conduit a prescrire hors des indications et recommandations de lˈautorisation de mise sur le marche, car les medicaments sont peu ou mal evalues chez lˈenfant. Ceci aExpand
Information du public sur les essais cliniques et la recherche
Resume Que ce soit pour restaurer l’image ternie de la recherche clinique vis-a-vis du grand public ou pour developper de nouvelles methodes de recrutement des volontaires sains ou des patients dansExpand
Quoi de neuf en oncologie pédiatrique
The significant progress made in pediatric oncology during recent years has been due to a major breakthrough in the field of molecular biology and the introduction of new therapeutic strategies thatExpand
Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.
The findings of this study indicate that adolescents should be included in intensive pediatric protocols and that new trials should be designed, inspired by pediatric protocols, for the treatment of young adults with ALL. Expand
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Despite moderate toxicity, objective response rates to temozolomide have been low, indicating that temozoomide has minimal activity in the high-grade gliomas of childhood. Expand
Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
Intensified chemotherapy incorporating alkylating agents for this subgroup of patients older than 10 years or with tumor greater than 5 cm may be preferred to the use of systematic lymphadenectomy to improve survival while minimizing the burden of therapy. Expand
Testing of new agents in childhood cancer preclinical models: meeting summary.
A workshop on pediatric preclinical testing, sponsored by the National Cancer Institute and the Children's Oncology Group Phase 1 Consortium, was held on June 26-27, 2001 in Bethesda, Maryland and produced a working inventory of available preclinical models. Expand
[Methodology and long-term follow-up of drug induced side effects in children (cancer, leukemia, AIDS, growth hormone)].
The development plan of a paediatric drug should include, long term follow up on the basis of pharmacological-toxicological and safety data, and aspects should be taken into account when modifying the protocol. Expand
Conduct of phase I trials in children with cancer.
  • M. Smith, M. Bernstein, +13 authors T. Vietti
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
This report summarizes current guidelines for the conduct of pediatric phase I trials and represents a consensus between American and European investigators. Expand
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
CPT-11 demonstrated significant activity against pPNET and neuroblastoma xenografts and five anti-cancer drugs commonly used in paediatric oncology or in clinical development were evaluated against SK-N-MC and IGR-N835. Expand